Clinical developments in the treatment of relapsed or relapsed and refractory multiple myeloma: impact of panobinostat, the first-in-class histone deacetylase inhibitor
Kimberly A Redic,1 Shannon M Hough,2 Erika M Price11College of Pharmacy, University of Michigan, 2Department of Pharmaceutical Services, University of Michigan Health System, Ann Arbor, MI, USABackground: Panobinostat is a new agent for the treatment of relapsed and refractory multiple myeloma (rrMM...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2016-05-01
|
| Series: | OncoTargets and Therapy |
| Subjects: | |
| Online Access: | https://www.dovepress.com/clinical-developments-in-the-treatment-of-relapsed-or-relapsed-and-ref-peer-reviewed-article-OTT |